Canada markets close in 3 hours 16 minutes

Sesen Bio, Inc. (SESN)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.7385+0.0072 (+0.98%)
As of 12:41PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous Close0.7313
Open0.7330
Bid0.7344 x 1100
Ask0.7396 x 1000
Day's Range0.7260 - 0.7498
52 Week Range0.3650 - 6.0400
Volume705,305
Avg. Volume4,296,982
Market Cap147.304M
Beta (5Y Monthly)0.58
PE Ratio (TTM)2.24
EPS (TTM)0.3300
Earnings DateAug 08, 2022 - Aug 12, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est0.56
  • Business Wire

    Sesen Bio Reports Second Quarter 2022 Financial Results and Business Update

    CAMBRIDGE, Mass., August 08, 2022--Sesen Bio (Nasdaq: SESN) today reported operating results for the second quarter ended June 30, 2022. During the quarter, the Company paused clinical development of its lead asset, Vicineum™ for the treatment of non-muscle invasive bladder cancer (NMIBC), and turned its primary focus to the assessment of potential strategic alternatives with the goal of maximizing shareholder value, which it believes will be complete by the end of 2022.

  • Zacks

    What's in the Cards for Sesen Bio's (SESN) Q2 Earnings?

    Sesen Bio's (SESN) Q2 performance is likely to reflect cost savings from the company's restructuring plans as the company continues to seek a potential partner for the further development of Vicineum.

  • Zacks

    Sesen (SESN) Halts Bladder Cancer Drug Development, Stock Down

    Sesen Bio (SESN) decides to pause the development of Vicineum in the United States. It also ended its 2016 licensing agreement with Roche in exchange for an upfront payment of $40 million.